Strongbridge Biopharma plc (SBBP) Expected to Post Quarterly Sales of $5.03 Million

Wall Street analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report sales of $5.03 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Strongbridge Biopharma’s earnings, with the lowest sales estimate coming in at $3.10 million and the highest estimate coming in at $5.83 million. Strongbridge Biopharma reported sales of $2.98 million during the same quarter last year, which indicates a positive year-over-year growth rate of 68.8%. The business is expected to report its next quarterly earnings report on Monday, March 11th.

On average, analysts expect that Strongbridge Biopharma will report full year sales of $18.53 million for the current fiscal year, with estimates ranging from $16.61 million to $19.30 million. For the next fiscal year, analysts forecast that the business will report sales of $28.69 million, with estimates ranging from $24.88 million to $30.03 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings results on Wednesday, October 31st. The biotechnology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.06). The firm had revenue of $5.35 million during the quarter, compared to the consensus estimate of $5.48 million.

A number of analysts have recently commented on SBBP shares. ValuEngine raised Strongbridge Biopharma from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. HC Wainwright set a $18.00 price target on Strongbridge Biopharma and gave the company a “buy” rating in a research note on Thursday, August 9th. Cantor Fitzgerald set a $17.00 price target on Strongbridge Biopharma and gave the company a “buy” rating in a research note on Wednesday, October 31st. Finally, BidaskClub cut Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 5th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $14.75.

Several institutional investors and hedge funds have recently modified their holdings of SBBP. Laurion Capital Management LP acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $101,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $110,000. Cubist Systematic Strategies LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $130,000. Jane Street Group LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $154,000. Finally, Citadel Advisors LLC acquired a new position in shares of Strongbridge Biopharma in the 3rd quarter valued at approximately $157,000. Institutional investors and hedge funds own 64.85% of the company’s stock.

Shares of SBBP stock opened at $5.23 on Friday. The company has a debt-to-equity ratio of 8.76, a current ratio of 3.38 and a quick ratio of 3.11. The stock has a market capitalization of $244.29 million, a PE ratio of -3.61 and a beta of -0.36. Strongbridge Biopharma has a one year low of $3.85 and a one year high of $9.25.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Further Reading: Reverse Stock Split

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply